01 Industry overview
The pharmaceutical packaging industry at a glance
The global pharmaceutical packaging market is estimated at $182.2 billion in 2026, with growth driven by biologics, injectables, serialization, and sustainability requirements.
- $182.2B[5]
- Global market estimate, 2026
- 9.9%[5]
- Forecast CAGR, 2026–2033
- 33.8%[5]
- North America share, 2025
- 76.4%[5]
- Primary packaging share, 2025
- Market size
- Grand View Research estimates the global pharmaceutical packaging market at $166.4 billion in 2025 and $182.2 billion in 2026. Mordor Intelligence estimates the 2026 market at $164.0 billion, illustrating the variation between research methodologies.[5][16]
- Forecast & CAGR
- Grand View Research forecasts the market to reach $353.1 billion by 2033, implying a 9.9% CAGR from 2026 to 2033. Mordor Intelligence forecasts $218.8 billion by 2031 at a 5.94% CAGR from 2026 to 2031.[5][16]
- Market share & regions
- North America accounted for 33.8% of global pharmaceutical packaging revenue in 2025, according to Grand View Research. In Europe, Germany held 22.3% of the regional market in 2025, while Asia-Pacific is identified as the fastest-growing major region in the global market.[5][16]
- Segmentation
- Primary packaging represented 76.4% of global revenue in 2025, plastics and polymers represented 36.6%, and pharmaceutical manufacturing accounted for 49.4% by end use. In Europe, plastics held a 52.03% material share and primary formats held a 62.10% share in 2025.[5][16]
- Key players & concentration
- The market includes Amcor, Becton Dickinson, AptarGroup, Gerresheimer, SCHOTT, Owens Illinois, West Pharmaceutical Services, Berry Global, SGD Pharma, and CCL Industries. Mordor Intelligence characterizes global market concentration as low, while Grand View Research lists a broad group of major suppliers across glass, plastics, closures, cartons, and drug-delivery systems.[16][5]
- Pricing
- A detailed, reliable global price index for pharmaceutical packaging was not identified. Available market analysis indicates that U.S. prices vary by product complexity, regulatory-compliance burden, and material specification, with specialized vials and prefilled syringes facing higher price pressure than standard formats.[17]
- Trends, drivers & challenges
- Demand is being supported by biologics, injectables, prefilled delivery systems, and contract manufacturing, while sustainability rules are increasing design and materials requirements. EU Regulation 2025/40 applies from August 12, 2026, and includes recycled-content requirements for some plastic packaging, although several medicinal-product packaging categories are exempt; U.S. DSCSA requirements continue to push interoperable package-level tracing.[16][18][19]
- Consumer behavior & competition
- At-home treatment is increasing demand for convenient formats: Mordor Intelligence specifically identifies prefilled syringes as gaining traction because they simplify home treatment and can reduce infusion-center costs. Competition spans global integrated suppliers and specialized regional manufacturers, with plastics leading the European market at 52.03% of revenue in 2025.[16]
- M&A
- Amcor completed its acquisition of Berry Global on April 30, 2025, in a transaction with a stated purchase price of $10.4 billion; Amcor expects $650 million of annual pretax synergies by fiscal 2028. Gerresheimer’s 2025 results included €330.9 million of Bormioli Pharma revenue following the acquisition completed in December 2024.[20][21]
- Regulation
- The EU Packaging and Packaging Waste Regulation entered into force on February 11, 2025, and applies from August 12, 2026; it establishes sustainability, labeling, and waste-management requirements and sets some 2030 recycled-content targets. In the United States, DSCSA is designed to enable interoperable electronic tracing of certain prescription drugs at package level, with FDA exemptions for small dispensers extending to November 27, 2027.[18][19]
- Latest news
- The most significant recent transaction affecting pharmaceutical packaging suppliers was Amcor’s April 30, 2025 completion of its Berry Global combination, creating a larger healthcare and consumer-packaging platform. Regulatory implementation was also a major 2026 development: the EU PPWR began applying on August 12, 2026, while FDA extended certain DSCSA small-dispenser exemptions through November 27, 2027.[22][18][19]
02 Ranking
Top 10 Companies in the Pharmaceutical Packaging Industry
The leading companies in the pharmaceutical packaging industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 22, 2026 · Next review December 22, 2026
Amcor stands out for flexible and rigid pharmaceutical packaging because it reported an 8.1% operating margin, while Sonoco Products focuses on rigid containers and healthcare packaging since it posted a 13.5% operating margin.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in flexible and rigid packaging
Amcor
CH
Ranked #1 · 9.4 · Flexible and rigid packaging
Why we picked it: It supplies flexible and rigid pharmaceutical packaging, with an 8.1% operating margin and R&D at 0.72% of revenue.
Leader in rigid containers & healthcare packaging
Sonoco Products
US
Ranked #2 · 9.2 · Rigid containers & healthcare packaging
Why we picked it: It works in rigid containers and healthcare packaging, backed by an an13.5% operating margin.
Leader in cartons & secondary packaging
Smurfit Westrock
IE
Ranked #3 · 8.9 · Cartons & secondary packaging
Why we picked it: It serves cartons and secondary pharmaceutical packaging, with revenue growth of 47.7% and an operating margin of 5.5%.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Amcor Flexible and rigid packaging · CH | 9.4 | 9.9 | 9.5 | 9.9 | 7.0 | |
Company snapshot · Amcor · Data as of November 22, 2026 Amcor is identified as a leading pharmaceutical packaging supplier.[6]
| |||||||
| 2 | Sonoco Products Rigid containers & healthcare packaging · US | 9.2 | 8.4 | 9.9 | 9.4 | 9.1 | |
Company snapshot · Sonoco Products · Data as of November 22, 2026 Sonoco is identified as a significant healthcare packaging market participant.[23]
| |||||||
| 3 | Smurfit Westrock Cartons & secondary packaging · IE | 8.9 | 8.4 | 9.3 | 9.4 | 9.1 | |
Company snapshot · Smurfit Westrock · Data as of November 22, 2026 Smurfit Westrock is ranked among major healthcare packaging market companies.[23]
| |||||||
| 4 | SGD Pharma Pharmaceutical glass containers · FR | 8.8 | 8.4 | 9.5 | 9.0 | 9.1 | |
Company snapshot · SGD Pharma · Data as of November 22, 2026 SGD Pharma produces Type I glass containers for injectable and other pharmaceutical applications.[24]
| |||||||
| 5 | Stevanato Group Drug-delivery systems · IT | 8.7 | 9.4 | 8.5 | 8.9 | 7.3 | |
Company snapshot · Stevanato Group · Data as of November 22, 2026 Stevanato makes pharmaceutical glass containers, ready-to-use systems and delivery devices.[25]
| |||||||
| 6 | SCHOTT Pharma Vials, ampoules, cartridges and prefillable syringes · DE | 8.5 | 9.4 | 8.3 | 8.1 | 7.5 | |
Company snapshot · SCHOTT Pharma · Data as of November 22, 2026 SCHOTT Pharma supplies containment and delivery systems for injectable drugs.[26]
| |||||||
| 7 | CCL Industries Pharmaceutical labels and specialty packaging · CA | 8.5 | 8.4 | 8.2 | 8.8 | 9.9 | |
Company snapshot · CCL Industries · Data as of November 22, 2026 CCL Industries is one of the global companies examined in pharmaceutical packaging.[27]
| |||||||
| 8 | Gerresheimer Glass, plastic containers and drug-delivery systems · DE | 8.3 | 9.8 | 8.2 | 7.0 | 7.6 | |
Company snapshot · Gerresheimer · Data as of November 22, 2026 Gerresheimer supplies drug-containment solutions, closures, delivery systems and medical devices.[21]
| |||||||
| 9 | Datwyler Elastomer closures and components · CH | 7.8 | 8.4 | 7.4 | 7.4 | 7.3 | |
Company snapshot · Datwyler · Data as of November 22, 2026 Datwyler is profiled among leading ready-to-use pharmaceutical packaging suppliers.[5]
| |||||||
| 10 | DWK Life Sciences Specialty glass pharmaceutical containers · DE | 7.4 | 7.0 | 7.0 | 7.5 | 7.3 | |
Company snapshot · DWK Life Sciences · Data as of November 22, 2026 DWK Life Sciences is listed among leading ready-to-use pharmaceutical packaging companies.[5]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 22, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 22). Top 10 companies in the pharmaceutical packaging industry. In Pharmaceutical Packaging Industry Statistics. Gitnux. https://gitnux.org/pharmaceutical-packaging-industry-statistics/#top-companies
Global pharmaceutical packaging market revenue share by region
APAC holds the largest share at 35%.
03 Trends & forecasts
Top 10 Pharmaceutical Packaging Industry Trends & Forecasts 2027
What is changing in the pharmaceutical packaging industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Biologics lift high-value containment
High confidenceThe global biopharmaceutical packaging market was estimated at $22.9 billion in 2025 and is forecast to reach $45.4 billion by 2033, with demand supported by biologics, vaccines, biosimilars, cell therapies and gene therapies. North America represented 39.8% of that market in 2025.[5]
Forecast 2027: In 2027, biologics-related packaging should continue growing faster than conventional oral-solid-dose packaging, increasing demand for high-performance vials, stoppers, cartridges and syringes. High-value containment products are likely to gain share of supplier revenue.
02Injectables expand vial demand
High confidenceSCHOTT Pharma reports production of more than 13 billion pharmaceutical drug containers annually across syringes, cartridges, vials and ampoules. Nipro expects injection-container demand to grow by approximately 4% annually, while packaging suitable for biologics is expected to grow by approximately 15% annually.[26][28]
Forecast 2027: In 2027, vial and ampoule volumes should rise steadily, but biologics-grade formats are likely to grow materially faster than standard injection containers. Capacity additions will focus increasingly on ready-to-use and high-quality formats.
03Prefilled systems gain home-treatment share
High confidenceAptar Pharma and Stevanato Group introduced next-generation prefilled syringes in 2025 for biologics and chronic-disease treatments, including an 8-millimeter needle that reduced injection force by 25% versus a traditional 12.7-millimeter needle. Aptar is also expanding prefilled-syringe component capacity in France and the United States.[29]
Forecast 2027: In 2027, prefilled syringes should continue taking share in chronic-care and self-injection applications. Growth will favor systems designed for autoinjector compatibility, lower injection force and easier patient handling.
04Autoinjector integration accelerates
High confidenceAptar, SHL Medical and Gerresheimer formed a 2025 collaboration focused on integrating prefilled syringes, rigid needle shields and coated plungers for biologic delivery. The work targets consistent activation, decapping, injection depth and break-loose and gliding-force performance.[29]
Forecast 2027: By 2027, pharmaceutical packaging specifications will increasingly be set at the combined syringe-device-system level rather than for individual components. Suppliers able to validate integrated systems should capture more development and commercial programs.
05High-performance elastomers command premiums
High confidenceWest Pharmaceutical Services reported $74.3 million of R&D spending in 2025, up 7.5% from 2024, driven partly by its prefillable-syringe system and engineered plastics and components. West also identifies biologics, high-value products and GLP-1 therapies as major growth drivers; GLP-1 elastomer revenue represented 10% of company revenue in the second quarter of 2026.[30]
Forecast 2027: In 2027, demand should remain strong for coated plungers, low-extractables stoppers and other high-performance elastomers. Pricing power is likely to remain strongest where components protect sensitive biologics or reduce contamination and compatibility risks.
06Container-closure testing tightens
High confidenceUSP <382> took effect on December 1, 2025 and introduced stricter functional testing for elastomeric components, including vial stoppers and prefilled-syringe components. Pharmaceutical companies are expected to validate the complete container-closure system rather than only individual components.[29]
Forecast 2027: In 2027, USP <382>-aligned testing should be routine in injectable development and qualification. The requirement will favor suppliers offering system-level data, validated combinations and technical support, while increasing development costs for smaller manufacturers.
07Contract packaging expands faster
High confidenceGrand View Research estimates the global healthcare contract-packaging-services market at $25.9 billion in 2025 and $28.4 billion in 2026, with a forecast of $61.1 billion by 2033 and an 11.6% CAGR. Primary packaging represented 56.6% of the market in 2025.[5]
Forecast 2027: In 2027, outsourcing should continue expanding as pharmaceutical and biotechnology companies seek compliant filling, assembly, serialization and specialized injectable-packaging capacity. Primary packaging and integrated services should grow faster than basic secondary-packaging work.
08Production capacity shifts toward resilience
High confidenceAptar is increasing prefilled-syringe component production capacity in both France and the United States, using robotic automation and digitalization. Fresenius also reported 2025 investments in automated packaging and additional formulation and filling capacity, including a planned investment of up to €45 million over coming years.[29][31]
Forecast 2027: In 2027, suppliers should continue adding regional capacity for injectables, prefilled systems and sterile products. Investment will prioritize automation, redundancy and shorter supply chains rather than relying solely on the lowest-cost production location.
09Serialization remains embedded
High confidenceThe FDA describes DSCSA as requiring interoperable electronic identification and tracing of certain prescription drugs at the package level. FDA exemptions for qualifying small dispensers extend until November 27, 2027, while the broader framework continues to require package-level traceability across the supply chain.[19]
Forecast 2027: In 2027, serialization and interoperable data exchange should remain a core packaging requirement in the United States. Packaging lines will increasingly combine coding, aggregation, verification and exception management, although small-dispenser exemptions will delay full adoption for part of the market.
10Sustainability rules reshape material choices
High confidenceEU Regulation 2025/40 establishes minimum recycled-content requirements for certain plastic packaging, including 30% for contact-sensitive PET packaging and 10% for contact-sensitive non-PET plastic packaging from 2030, while exempting certain immediate and outer medicinal-product packaging where quality requirements apply. The regulation applies from August 12, 2026.[18]
Forecast 2027: In 2027, pharmaceutical packaging suppliers will intensify qualification of recycled, recyclable and downgauged materials, especially for secondary and non-contact formats. Immediate-contact medicinal packaging will change more cautiously because safety and product-quality exemptions remain important.
04 Statistics
Technology
Automation expansion is planned: 64% of Healthcare Packaging readers planned to add automation in 2026, alongside 42% of manufacturers digitizing documentation and regulatory reporting in 2025.
Automation and robotics in the pharmaceutical packaging industry
- 64% of Healthcare Packaging readers planned to add automation in 2026, indicating planned automation expansion among the publication’s pharmaceutical-packaging-oriented audience.[1]
- 42% of pharmaceutical manufacturers reported expanding automation or reducing manual processes in 2025, based on PMMI’s pharmaceutical manufacturing survey covering end users and OEMs.[2]
- 42% of pharmaceutical manufacturers reported increasing automation in 2025, while 53% adopted predictive or preventive maintenance.[3]
AI in production and inspection in the pharmaceutical packaging industry
- 17% of European pharmaceutical manufacturing decision-makers reported current use of digital twins in late 2024 or early 2025, a measured AI-adjacent digital-production adoption indicator.[4]
- 26% of pharmaceutical manufacturing OEM respondents planned AI-supported processes, according to PMMI’s 2025 pharmaceutical manufacturing survey.[2]
- 43% of pharmaceutical leaders ranked predicting and preventing quality defects among their top three expected AI value areas in 2025.[1]
Digital operations in the pharmaceutical packaging industry
- 63% of life-sciences organizations continued using paper-based processes for critical production-line changeovers in 2025, including pharmaceutical operations.[1]
- 17% of European pharmaceutical manufacturing decision-makers reported using digital twins of their facilities in late 2024 or early 2025.[4]
- 42% of pharmaceutical manufacturers reported digitizing documentation and regulatory reporting in 2025, including packaging-related compliance processes.[2]
05 Statistics
Market Intelligence
The 2026 market estimate sits at $182.2 billion per one source, with 2026 estimates varying by methodology. Segment shares show primary packaging at 76.4% in 2025.
Market size, volume and shipments in the pharmaceutical packaging industry
- USD 166.4 billion was the global pharmaceutical packaging market value in 2025, covering primary, secondary and tertiary packaging by material, product, end use and region.[5]
- USD 174.85 billion was the global pharmaceutical packaging market value in 2025, covering packaging by raw material, type, drug-delivery mode and region.[6]
- USD 71.3 billion was the global pharmaceutical packaging market value in 2025, using Freedonia’s category definition for pharmaceutical packaging products and services.[7]
- USD 152.3 billion was the global pharmaceutical packaging market value in 2024, covering packaging products and materials across global regions.[8]
Forecast growth and shipments in the pharmaceutical packaging industry
- 7.2% is the projected compound annual growth rate for global pharmaceutical packaging market value from 2025 to 2030, with the category defined as pharmaceutical packaging across global product and material segments.[9]
- 9.9% is the projected compound annual growth rate for global pharmaceutical packaging market value from 2026 to 2033; the category covers primary, secondary and tertiary packaging by material, product, end use and region.[5]
- 15.8% is the projected compound annual growth rate for global pharmaceutical packaging market value from 2025 to 2030; the category covers packaging by raw material, type, drug-delivery mode and region.[6]
06 Statistics
Strategy & Growth
Capacity and assembly moves appear across the value chain, including a 545,000 square feet expansion planned at PCI Pharma Services in Rockford for drug-device assembly and packaging.
Capacity expansion in the pharmaceutical packaging industry
- One additional packaging line was expected to double Ritedose Pharmaceuticals’ capacity for individually wrapped single-vial medications, with service planned for early summer 2025.[10]
- 545,000 square feet of expansion was planned at PCI Pharma Services’ Rockford, Illinois campus for drug-device assembly and packaging, with operations scheduled for the third quarter of 2025.[11]
- CHF 10.6 million was invested in 2024 in capacity expansion and product development by Perlen Packaging, a pharmaceutical-film supplier; the company reported the investment for its global operations.[12]
07 Statistics
Product & Standards
Standards stay anchored to ISO 15378:2017 as the latest review-and-confirmation year shown for that edition. Recycled-content adoption shows up, with 27% using post-consumer-recycled material in 2025.
Standards, grades and specs for pharmaceutical packaging
- 2023 is the latest review-and-confirmation year shown for ISO 15378:2017, which therefore remains the current edition for primary medicinal-product packaging materials.[13]
- 1 amendment is recorded for ISO 15378:2017, the international standard for primary packaging materials for medicinal products.[13]
- 2017 is the edition year of ISO 15378 for primary packaging materials for medicinal products, incorporating ISO 9001:2015 and pharmaceutical good-manufacturing-practice requirements.[13]
Materials, inputs and substitution in pharmaceutical packaging
- 27% of surveyed pharmaceutical manufacturers reported using post-consumer-recycled material in pharmaceutical packaging designs in 2025.[3]
- 15% to 30% post-consumer-recycled content was being tested in secondary and tertiary pharmaceutical packaging plastics at Gilead’s largest finished-goods packaging facilities in 2024.[14]
- 22% of surveyed pharmaceutical manufacturers reported using lightweighting or material reduction in pharmaceutical packaging designs in 2025.[3]
08 Statistics
Trade & Footprint
Import duty rates for relevant plastics HS headings are set at 3% under the 2026 HTS Revision 23 across the listed plastics packaging categories.
Tariffs and trade policy for pharmaceutical packaging
- 3% general U.S. import duty applies to HTS 3923.30.00, plastic carboys, bottles, flasks and similar packing articles; this broader plastics category includes pharmaceutical packaging but is not pharma-specific, under 2026 HTS Revision 23.[15]
- 3% general U.S. import duty applies to HTS 3923.29.00, plastics packaging articles of plastics other than ethylene polymers; this broader plastics category includes pharmaceutical packaging but is not pharma-specific, under 2026 HTS Revision 23.[15]
- 3% general U.S. import duty applies to HTS 3923.90.00, other plastic articles for conveying or packing goods; this broader plastics category includes pharmaceutical packaging but is not pharma-specific, under 2026 HTS Revision 23.[15]
Key questions about the pharmaceutical packaging industry
What is the pharmaceutical packaging market size in 2026?
How fast is the market expected to grow from 2026 to 2033?
Which companies lead the pharmaceutical packaging industry?
Which technology shifts show up in packaging-related operations in 2025 and 2026 plans?
Is the market structurally concentrated or fragmented?
What regulation timing affects packaging design and materials starting August 2026?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 22). Pharmaceutical Packaging Industry Statistics. Gitnux. https://gitnux.org/pharmaceutical-packaging-industry-statistics
Samuel Norberg. "Pharmaceutical Packaging Industry Statistics." Gitnux, 22 Nov 2026, https://gitnux.org/pharmaceutical-packaging-industry-statistics.
Samuel Norberg. 2026. "Pharmaceutical Packaging Industry Statistics." Gitnux. https://gitnux.org/pharmaceutical-packaging-industry-statistics.
Sources & references
31 sources cited across this report
healthcarepackaging.com
mma.prnewswire.com
pmmi-fonteva.s3.us-east-1.amazonaws.com
hexagon.com
grandviewresearch.com
marketsandmarkets.com
- freedoniagroup.com
stratviewresearch.com
bccresearch.com
prnewswire.com
pci.com
- cph.ch
iso.org
gilead.com
hts.usitc.gov
mordorintelligence.com
indexbox.io
eur-lex.europa.eu
fda.gov
sec.gov
gerresheimer.com
packagingsolutions.amcor.com
gminsights.com
reportprime.com
ir.stevanatogroup.com
schott-pharma.com
plasticstoday.com
nipro.co.jp
aptar.com
investor.westpharma.com
report.fresenius.com